SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
Portfolio Pulse from
Faruqi & Faruqi, LLP is investigating potential securities law violations by Neumora Therapeutics (NMRA) related to misleading statements about its experimental depression treatment. On January 2, 2025, the company announced its Phase III Koastal-1 trial failed, causing the stock to plummet 81% to $1.97 per share. The law firm alleges the company made false statements about trial criteria and data adequacy.
March 23, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The company is under investigation for potentially misleading investors about its drug trial methodology and results, which led to a significant stock price decline.
The lawsuit alleges material misrepresentations about trial design and data, which could result in significant legal and financial consequences for the company.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100